Targeting IL-2

an unexpected effect in treating immunological diseases

Congxiu Ye, David Brand, Song G. Zheng

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Regulatory T cells (Treg) play a crucial role in maintaining immune homeostasis since Treg dysfunction in both animals and humans is associated with multi-organ autoimmune and inflammatory disease. While IL-2 is generally considered to promote T-cell proliferation and enhance effector T-cell function, recent studies have demonstrated that treatments that utilize low-dose IL-2 unexpectedly induce immune tolerance and promote Treg development resulting in the suppression of unwanted immune responses and eventually leading to treatment of some autoimmune disorders. In the present review, we discuss the biology of IL-2 and its signaling to help define the key role played by IL-2 in the development and function of Treg cells. We also summarize proof-of-concept clinical trials which have shown that low-dose IL-2 can control autoimmune diseases safely and effectively by specifically expanding and activating Treg. However, future studies will be needed to validate a better and safer dosing strategy for low-dose IL-2 treatments utilizing well-controlled clinical trials. More studies will also be needed to validate the appropriate dose of IL-2/anti-cytokine or IL-2/anti-IL-2 complex in the experimental animal models before moving to the clinic.

Original languageEnglish (US)
Article number2
JournalSignal Transduction and Targeted Therapy
Volume3
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Immune System Diseases
Interleukin-2
Regulatory T-Lymphocytes
Autoimmune Diseases
T-Lymphocytes
Immune Tolerance
Controlled Clinical Trials
Homeostasis
Therapeutics
Animal Models
Cell Proliferation
Clinical Trials
Cytokines

All Science Journal Classification (ASJC) codes

  • Genetics
  • Cancer Research

Cite this

Targeting IL-2 : an unexpected effect in treating immunological diseases. / Ye, Congxiu; Brand, David; Zheng, Song G.

In: Signal Transduction and Targeted Therapy, Vol. 3, No. 1, 2, 01.12.2018.

Research output: Contribution to journalReview article

@article{c1591edbff4a4239ad82bc6b9f9414cb,
title = "Targeting IL-2: an unexpected effect in treating immunological diseases",
abstract = "Regulatory T cells (Treg) play a crucial role in maintaining immune homeostasis since Treg dysfunction in both animals and humans is associated with multi-organ autoimmune and inflammatory disease. While IL-2 is generally considered to promote T-cell proliferation and enhance effector T-cell function, recent studies have demonstrated that treatments that utilize low-dose IL-2 unexpectedly induce immune tolerance and promote Treg development resulting in the suppression of unwanted immune responses and eventually leading to treatment of some autoimmune disorders. In the present review, we discuss the biology of IL-2 and its signaling to help define the key role played by IL-2 in the development and function of Treg cells. We also summarize proof-of-concept clinical trials which have shown that low-dose IL-2 can control autoimmune diseases safely and effectively by specifically expanding and activating Treg. However, future studies will be needed to validate a better and safer dosing strategy for low-dose IL-2 treatments utilizing well-controlled clinical trials. More studies will also be needed to validate the appropriate dose of IL-2/anti-cytokine or IL-2/anti-IL-2 complex in the experimental animal models before moving to the clinic.",
author = "Congxiu Ye and David Brand and Zheng, {Song G.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41392-017-0002-5",
language = "English (US)",
volume = "3",
journal = "Signal Transduction and Targeted Therapy",
issn = "2095-9907",
publisher = "Springer Nature",
number = "1",

}

TY - JOUR

T1 - Targeting IL-2

T2 - an unexpected effect in treating immunological diseases

AU - Ye, Congxiu

AU - Brand, David

AU - Zheng, Song G.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Regulatory T cells (Treg) play a crucial role in maintaining immune homeostasis since Treg dysfunction in both animals and humans is associated with multi-organ autoimmune and inflammatory disease. While IL-2 is generally considered to promote T-cell proliferation and enhance effector T-cell function, recent studies have demonstrated that treatments that utilize low-dose IL-2 unexpectedly induce immune tolerance and promote Treg development resulting in the suppression of unwanted immune responses and eventually leading to treatment of some autoimmune disorders. In the present review, we discuss the biology of IL-2 and its signaling to help define the key role played by IL-2 in the development and function of Treg cells. We also summarize proof-of-concept clinical trials which have shown that low-dose IL-2 can control autoimmune diseases safely and effectively by specifically expanding and activating Treg. However, future studies will be needed to validate a better and safer dosing strategy for low-dose IL-2 treatments utilizing well-controlled clinical trials. More studies will also be needed to validate the appropriate dose of IL-2/anti-cytokine or IL-2/anti-IL-2 complex in the experimental animal models before moving to the clinic.

AB - Regulatory T cells (Treg) play a crucial role in maintaining immune homeostasis since Treg dysfunction in both animals and humans is associated with multi-organ autoimmune and inflammatory disease. While IL-2 is generally considered to promote T-cell proliferation and enhance effector T-cell function, recent studies have demonstrated that treatments that utilize low-dose IL-2 unexpectedly induce immune tolerance and promote Treg development resulting in the suppression of unwanted immune responses and eventually leading to treatment of some autoimmune disorders. In the present review, we discuss the biology of IL-2 and its signaling to help define the key role played by IL-2 in the development and function of Treg cells. We also summarize proof-of-concept clinical trials which have shown that low-dose IL-2 can control autoimmune diseases safely and effectively by specifically expanding and activating Treg. However, future studies will be needed to validate a better and safer dosing strategy for low-dose IL-2 treatments utilizing well-controlled clinical trials. More studies will also be needed to validate the appropriate dose of IL-2/anti-cytokine or IL-2/anti-IL-2 complex in the experimental animal models before moving to the clinic.

UR - http://www.scopus.com/inward/record.url?scp=85056536289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056536289&partnerID=8YFLogxK

U2 - 10.1038/s41392-017-0002-5

DO - 10.1038/s41392-017-0002-5

M3 - Review article

VL - 3

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

SN - 2095-9907

IS - 1

M1 - 2

ER -